Mediclinic International plc Directorate Change (7640V)

TIDMMDC

RNS Number : 7640V

Mediclinic International plc

25 July 2018

Mediclinic International plc

(Incorporated in England and Wales)

Company Number 8338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" or "the Company")

25 July 2018

DIRECTORATE CHANGES

APPOINTMENT OF DR ANJA OSWALD AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Mediclinic announces that Dr Anja Oswald is to join its Board as an independent non-executive director with effect from 25 July 2018.

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

"The Board is delighted to welcome Dr Oswald as an independent non-executive director of the Company. Her expertise in the Swiss healthcare system, health politics and the regulatory environment, surgical medicine, general management and the development of business strategies will be valuable additions to the Board."

Dr Oswald is the CEO of the Klinik Sonnenhalde, a well-established private clinic for psychiatry and psychotherapy with inpatients, day-care clinics and outpatients in Riehen, Switzerland and is Vice-President of the Association of Private Hospitals in Basel. Prior to this, she was Head of Medical and Pharmaceutical Services and Deputy Medical Officer in the Department of Health of the Cantonal Government in Basel and a member of various cantonal, regional and national committees. Dr Oswald was also CEO of a start-up company in the health care sector and worked several years as a Medical Doctor in different hospitals.

Dr Oswald holds a Masters in Business Administration from the Rochester-Berne Executive MBA, a Doctorate in Medicine from the University of Basel specialising in orthopaedic surgery and traumatology as well as in sports medicine. She passed the Board School at the International Centre of Corporate Governance of the University of St. Gallen.

There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment. Dr Oswald's fees will amount to GBP80,000 per annum, including the fees payable for committee memberships referred to in more detail below, which is in line with current independent non-executive directors.

CHANGES TO COMMITTEE MEMBERSHIPS

The Board also agreed to certain other changes to the membership of its committees. As announced on 29 March 2018, following the resignations of Ms Nandi Mandela and Prof Dr Robert Leu as independent non-executive directors at the conclusion of the Annual General Meeting to be held today, their memberships of all Board committees will cease at that point. Accordingly, the Company confirms the following Board committee changes:

Remuneration Committee:

With effect from 25 July 2018, Prof Dr Robert Leu will step down as a member of the Remuneration Committee and Dr Anja Oswald will be appointed as a member of the Remuneration Committee.

Nomination Committee:

With effect from 25 July 2018, Prof Dr Robert Leu and Mr Trevor Petersen will step down as members of the Nomination Committee and will be replaced on that committee by Dr Felicity Harvey and Dr Anja Oswald.

Clinical Performance and Sustainability Committee:

With effect from 25 July 2018, Prof Dr Robert Leu, Mr Danie Meintjes and Ms Nandi Mandela will step down as members of the Clinical Performance and Sustainability Committee. Mr Seamus Keating and Dr Ronnie van der Merwe will become members of the Clinical Performance and Sustainability Committee from that date.

Investment Committee:

With effect from 25 July 2018, Mr Seamus Keating will step down as a member of the Investment Committee and Dr Ronnie van der Merwe will be appointed as a member of the Investment Committee.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAPGUCPMUPRGWA

(END) Dow Jones Newswires

July 25, 2018 09:45 ET (13:45 GMT)